ArticleJournal of the American College of Cardiology2018
Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis.
Open access · hybridAbstract read
In one paragraph
Article in Journal of the American College of Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.
- Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling.Scientific reports · 2025Pooled it
- Rare-Earth Nanomaterials for Advanced Theranostics of Atherosclerosis.Chemical & biomedical imaging · 2026Review
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- [EJNMMI research · 2026Article
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
- Review
- CD40 drives tumor growth in non-small cell lung cancer via non-canonical immune-independent mechanisms.Cancer letters · 2026Article
- How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- T cells in cardiovascular disease: solved and unsolved mysteries.Science China. Life sciences · 2026Review
- Engineered immune-driven theranostics for clinical cardiology.Military Medical Research · 2025Review
- Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- LIGHT/TNFSF14 Levels in Carotid Plaques Are Associated With Symptomatic Cerebrovascular Disease.Journal of stroke · 2025Article
- A New Approach to the Diagnosis and Treatment of Cardiovascular Diseases.Pharmaceutics · 2025Review
- A programmable platelet theranostic platform for adaptive multi-stage delivery and synergistic immunotherapy in atherosclerosis.Nature communications · 2025Article
- Lactate Metabolism and Lactylation Modification: New Opportunities and Challenges in Cardiovascular Disease.MedComm · 2025Review
- Mitigating cardiac allograft vasculopathy in a murine model via CD40-TRAF6 blockade and cyclosporin A synergy.Scientific reports · 2025Article
- Lysosomal zinc nanomodulation blocks macrophage pyroptosis for counteracting atherosclerosis progression.Science advances · 2025Article
- The role of soluble CD40L in autoimmune diseases.Journal of translational autoimmunity · 2025Review
- Probiotic membrane vesicles ameliorate atherosclerotic plaques by promoting lipid efflux and polarization of foamy macrophages.Journal of nanobiotechnology · 2025Article
- CD40-TRAF6 inhibition suppresses cardiovascular inflammation, oxidative stress and functional complications in a mouse model of arterial hypertension.Redox biology · 2025Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
36 authors at 11 institutions in 3 countries.
Tom T P SeijkensDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.
Claudia M van TielDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Pascal J H KustersDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Dorothee AtzlerDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany; Walther-Straub-Institut for Pharmacology and Toxicology, Ludwig-Maximilians-University, Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
Oliver SoehnleinInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
Barbara ZarzyckaDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
Suzanne A B M AartsDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Marnix LameijerDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Marion J GijbelsDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Department of Molecular Genetics, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
Linda BeckersDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Myrthe den ToomDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Bram SlütterDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Johan KuiperDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Johan DucheneInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.
Maria AslaniInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.
Remco T A MegensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany; Department of Biomedical Engineering, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
Cornelis van 't VeerCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Gijs KooijDepartment of Molecular Cell Biology and Immunology, Neuroscience Campus Amsterdam, VU Medical Center, Amsterdam, the Netherlands.
Roy SchrijverGerman Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
Marten A HoeksemaDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Louis BoonBioceros BV, Utrecht, the Netherlands.
Francois FayTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Jun TangBioceros BV, Utrecht, the Netherlands; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Samantha BaxterTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Aldo JongejanDepartment of Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Perry D MoerlandDepartment of Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Gert VriendCentre for Molecular and Biomolecular Informatics (CMBI), Radboud University Medical Center, Nijmegen, the Netherlands.
Boris BleijlevensDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Edward A FisherDivision of Cardiology, Department of Medicine, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York.
Raphael DuivenvoordenDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Norbert GerdesInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany; Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.
Menno P J de WintherDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.
Gerry A NicolaesDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
Willem J M MulderDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Christian WeberInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
Esther LutgensDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany. Electronic address: E.Lutgens@amc.uva.nl.
Amsterdam UMC Location University of Amsterdam · NLUniversity of Amsterdam · NLLudwig-Maximilians-Universität München · DEMaastricht University · NLCentre for Human Drug Research · NLIcahn School of Medicine at Mount Sinai · USAmsterdam Neuroscience · NLGerman Centre for Cardiovascular Research · DENew York University · USPolpharma Biologics (Netherlands) · NLRadboud University Medical Center · NL
Funding
Translational imaging and nanomedicine in inflammatory atherosclerosisP01HL131478 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zahi A. Fayad · 2017 to 2026
$24.3MPET/MRI to study nanotherapy in atherosclerosisR01HL125703 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM · 2015 to 2018
$2.4MAnti-inflammatory nanoparticle formulations to treat atherosclerosisR01HL118440 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM, NAHRENDORF, MATTHIAS · 2014 to 2017
$2.3MNHLBI NIH HHS P01 HL131478NHLBI NIH HHS R01 HL118440NHLBI NIH HHS R01 HL125703
Abstract
backgroundDisrupting the costimulatory CD40-CD40L dyad reduces atherosclerosis, but can result in immune suppression. The authors recently identified small molecule inhibitors that block the interaction between CD40 and tumor necrosis factor receptor-associated factor (TRAF) 6 (TRAF-STOPs), while leaving CD40-TRAF2/3/5 interactions intact, thereby preserving CD40-mediated immunity.
objectivesThis study evaluates the potential of TRAF-STOP treatment in atherosclerosis.
methodsThe effects of TRAF-STOPs on atherosclerosis were investigated in apolipoprotein E deficient (Apoe
resultsTRAF-STOP treatment of young Apoe
conclusionsTRAF-STOPs can overcome the current limitations of long-term CD40 inhibition in atherosclerosis and have the potential to become a future therapeutic for atherosclerosis.
Indexed as
Aniline CompoundsAnimalsAtherosclerosisCD40 LigandCell Culture TechniquesCell MovementDisease Models, AnimalHumansMacrophagesMiceMice, Inbred C57BLMonocytesPropiophenonesSignal TransductionTNF Receptor-Associated Factor 6Aniline CompoundsCD40 LigandPropiophenonesSMI 6860766TNF Receptor-Associated Factor 6atherosclerosisdrug developmentimmunologyinflammationnanotechnology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.